StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –

Novartis Research & Development by Quarter

Research & Development ($M)

QuarterlyAnnual

Novartis Research & Development: $5,150M in Q3 2026, up 74.9% from a year earlier. That is the highest of the 37 quarters on record here.

Latest, Q3 2026
5,150
Period ended Sep 30, 2026
Change on a year earlier
+74.9%
2,944 in Q3 2025
History
37 quarters
Since Q2 2017
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“|| Research and development | – 5 150 | – 2 944”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Postgres DB + Form 6-K.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedResearch & Development ($M)Year on yearSource
Q3 2026Sep 30, 20265,150+74.9%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20262,847+4.4%Novartis 6-K (0001114448-26-000012, filed 2026-07-21) ↗
Q1 2026Mar 31, 20262,740+15.8%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 20253,163+11.3%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 20252,944+23.1%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 20252,727+15.2%Novartis 6-K (0001370368-25-000012, filed 2025-07-17) ↗
Q1 2025Mar 31, 20252,366-2.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 20242,842+10.7%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 20242,392-39.1%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 20242,367+2.7%Novartis 6-K (0001370368-24-000019, filed 2024-07-18) ↗
Q1 2024Mar 31, 20242,421-6.0%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 20232,567+15.8%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 20233,925+54.4%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 20232,304-7.8%Novartis 6-K (0001370368-24-000019, filed 2024-07-18) ↗
Q1 2023Mar 31, 20232,575+11.0%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 20222,216-8.0%Novartis Form 6-K (0001370368-24-000007) ↗

Cite this data

StockData. (2026). Novartis Research & Development ($M), quarterly Q2 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-is-rd

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.